| Li, Hui |
NCT05469685: Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication |
|
|
| Completed | 4 | 914 | RoW | Vonoprazan, Amoxicillin | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection | 08/23 | 09/23 | | |
NCT05649540: Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori |
|
|
| Active, not recruiting | 4 | 900 | RoW | Vonoprazan, Amoxicillin | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（） |
|
|
| Recruiting | 3 | 2105 | RoW | 14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management | Capital Medical University | Acute Ischemic Stroke, Anterior Circulation Brain Infarction | 11/26 | 02/27 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 12/24 | 12/26 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT05987371: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. |
|
|
| Recruiting | 2 | 72 | RoW | TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 01/24 | 03/24 | | |
NCT06254521: The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Tislelizumab combined with chemotherapy | First Affiliated Hospital of Guangxi Medical University | Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III | 12/24 | 12/27 | | |
SAV, NCT05736965: A Study of Selinexor in Combination With Azacitidine and Venetoclax ( Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 58 | RoW | Selinexor, xpo1 inhibitor, Azacitidine, Venetoclax, ABT199 | Shanghai Tong Ren Hospital | AML, Adult | 03/25 | 04/27 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) |
|
|
| Completed | N/A | 1000 | RoW | | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University | COVID-19, Liver Disease, Vaccine Reaction | 01/22 | 05/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease |
|
|
| Recruiting | N/A | 286 | RoW | DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease | 06/22 | 04/23 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
| Recruiting | N/A | 100 | RoW | Dopamine, Fractional Flow Reserve, Renal, Renal artery stenting | Peking University First Hospital | Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial | 03/25 | 03/25 | | |
NCT06359795: Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease |
|
|
| Recruiting | N/A | 50 | RoW | 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT | Peking University Third Hospital | Thyroid Eye Disease | 12/27 | 12/27 | | |
NCT05044182: Decompression and Drainage Seton for Treatment of High Horseshoe Anal Fistula |
|
|
| Recruiting | N/A | 92 | RoW | Decompression and drainage seton, Cutting seton | China-Japan Friendship Hospital | Anal Fistula | 12/23 | 01/24 | | |
NCT06495736: Application of Rapid On-site Evaluation in Lymph Node Biopsy of Breast Cancer |
|
|
| Recruiting | N/A | 400 | RoW | Experimental: ROSE technique stain | Yunnan Cancer Hospital | Breast Cancer | 02/26 | 02/26 | | |
NCT06509555: Correlation Between Serum TK1 and Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy |
|
|
| Recruiting | N/A | 200 | RoW | non-intervention | Yunnan Cancer Hospital | Breast Neoplasms, TK1 | 02/26 | 02/26 | | |
REAL, NCT05970159: Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery |
|
|
| Recruiting | N/A | 480 | RoW | | Shanghai Zhongshan Hospital, Takeda | Hepatocellular Carcinoma | 06/24 | 03/25 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
NCT05715710: Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease |
|
|
| Recruiting | N/A | 200 | RoW | | Zigong No.1 Peoples Hospital | Cerebral Small Vessel Disease | 09/25 | 09/25 | | |
NCT05046925: PACU for Postoperative Care After Major Thoracic and Abdominal Surgery |
|
|
| Not yet recruiting | N/A | 18000 | RoW | postoperatively transferral to PACU, 24-hour PACU group, postoperatively transferral to ICU, 24-hour ICU group | First Affiliated Hospital of Zhejiang University | Anesthesia, Surgery--Complications | 12/23 | 12/23 | | |
| Gong, Xuhai |
| No trials found |
